Every 8-K that BIOATLA INC (BCAB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BCAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BCAB filings page.
BioAtla, Inc. (BCAB) disclosed that Dr. Eric Sievers resigned as chief medical officer on September 25, 2026, and will consult through June 30, 2027. For requested consulting services through December 31, 2026, he is eligible for a one-time $159,000 payment contingent on the company achieving certain capital-raising milestones by that date. Services from January 1 through June 30, 2027, are paid hourly at a rate proportional to his base salary at separation.
On September 24, 2026, the board reinstated selected retention-bonus terms for CEO Jay M. Short and CFO Christian Vasquez, subject to milestones by December 31, 2026. Short's $440,892 target requires 100% achievement; Vasquez's $148,888 target pays proportionally from 80% to 120% for results within 20% below or above the milestone, with no payout if it is missed by more than 20%. Both must be employed and in good standing at payout. Separate performance bonuses of $220,000 for Short and $75,000 for Vasquez depend on milestones by March 31, 2027; payment is due by April 30, 2027, subject to the same employment condition.
BioAtla, Inc. (BCAB) reports that the Nasdaq Listing and Hearing Review Council has affirmed an earlier Nasdaq Hearings Panel decision to delist the company’s common stock. The action is based on prior non-compliance with Nasdaq’s $1.00 bid price requirement and the $2.5 million stockholders’ equity standard, despite a prior period of compliance with the alternative $35 million market value of listed securities standard. Unless the Nasdaq Board calls the matter for review, trading on Nasdaq is expected to be suspended at the opening of business on August 31, 2026, followed by the filing of a Form 25-NSE to remove the listing and registration. BioAtla expects its shares to be immediately eligible for quotation on the OTC Markets system under the symbol BCAB, and discloses that this change may materially adversely affect trading price and volume and make it harder for stockholders to buy or sell shares. The company’s strategic review process, initiated in March 2026 to explore options to maximize shareholder value, remains ongoing.
BioAtla, Inc. held its 2026 annual meeting of stockholders on July 16, 2026, with 906,983 shares of common stock represented in person virtually or by proxy, approximately 55% of the total outstanding shares eligible to be voted. Stockholders considered director elections, auditor ratification and executive compensation.
Two Class III directors, Jay M. Short, Ph.D. and Edward Williams, were elected to three-year terms. Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A non-binding advisory resolution approving the compensation of named executive officers also received stockholder approval.
BioAtla, Inc. is implementing a reverse stock split through an internal merger structure. On April 2, 2026, the company filed a Certificate of Merger in Delaware for a merger between BioAtla and its wholly owned subsidiary, BA Merger Sub, Inc.
At the effective time of the merger on April 6, 2026 at 12:01 a.m. Eastern Time, BA Merger Sub will merge into BioAtla, with BioAtla continuing as the surviving corporation. Every fifty (50) shares of BioAtla common stock issued and outstanding or held as treasury stock will be converted into one (1) share of common stock of the surviving corporation.
The company’s Amended and Restated Certificate of Incorporation will remain in effect for the surviving corporation. The full Certificate of Merger is available as Exhibit 99.1, and BioAtla’s common stock will continue to trade on The Nasdaq Capital Market under the symbol BCAB.
BioAtla, Inc. reported a full-year 2025 net loss of $59.6 million and a fourth-quarter 2025 net loss of $9.8 million, reflecting lower collaboration revenue and high R&D spending. R&D expenses were $43.6 million in 2025, down from $63.1 million, while G&A expenses fell to $17.7 million from $21.8 million after workforce reductions.
Cash and cash equivalents declined to $7.1 million as of December 31, 2025, with total assets of $13.8 million and a stockholders’ deficit of $36.2 million, indicating financial strain. The company has fully converted its Pre-paid Advance Agreements into common stock and is using a Standby Equity Purchase Agreement to extend runway.
BioAtla’s board initiated a formal process to explore strategic options, including potential asset sales, licensing deals, partnerships, or other transactions, and implemented additional reductions in force and cost-containment measures. While continuing key programs such as the Phase 1 BA3182 study and advanced assets Ozuriftamab Vedotin, Mecbotamab Vedotin, and Evalstotug, the company warns that clinical development may be limited or delayed pending the outcome of this strategic review.
BioAtla, Inc. reports that stockholders approved an internal merger with its wholly owned subsidiary BA Merger Sub, Inc., which will include a 1-for-50 consolidation of its common stock at the merger’s effective time. The company plans to complete the merger and share consolidation as soon as Nasdaq notice requirements are satisfied.
Separately, BioAtla’s board approved 2026 cash retention bonuses for key executives in place of a regular bonus plan or salary increases. The CFO and Chief Medical Officer can each earn milestone-based bonuses tied to financial and capital raising goals in May and August 2026, while the CEO’s bonus is a single milestone-based payment tied to August 2026 objectives.
BioAtla, Inc. has initiated a formal review of strategic options, including selling preclinical and clinical assets, licensing deals, partnerships or other corporate transactions, while undertaking a major restructuring with a workforce reduction of approximately 70% to lower operating expenses.
The company reported preliminary cash and cash equivalents of about $7.1 million as of December 31, 2025, has fully repaid the $7.5 million advanced under its pre-paid agreements, and may sell up to $15.0 million of common stock under a standby equity purchase agreement, subject to conditions. A planned $40 million SPV transaction is under renegotiation.
Nasdaq has called for review of a prior decision to suspend and delist the stock for bid-price and stockholders’ equity deficiencies; BioAtla’s shares continue trading during this process, whose outcome is uncertain. The company also announced the termination of its Chief Financial Officer, Richard Waldron, effective March 2, 2026, with severance and accelerated vesting of 37,875 restricted stock units, and the appointment of Chris Vasquez as the new Chief Financial Officer.
BioAtla, Inc. reports that the Nasdaq Listing and Hearing Review Council has called for review of Nasdaq’s February 6, 2026 decision to suspend trading and delist its shares. The Council’s action automatically stays any suspension, so BioAtla’s common stock will continue trading on Nasdaq during the review, which may take several weeks to a few months. The earlier determination was based on non-compliance with Nasdaq’s $1.00 minimum bid price rule and the $2.5 million stockholders’ equity requirement, despite prior compliance with the $35 million market value of listed securities threshold. BioAtla states it believes Nasdaq’s actions have caused and will cause irreparable harm and requested immediate review. The company cautions there is no assurance the review will result in its stock remaining listed on Nasdaq and highlights broader business risks, including going concern issues and the need for additional funding to advance its CAB platform and product candidates.
BioAtla, Inc. reports that a Nasdaq Hearings Panel has decided to suspend trading of its common stock on Nasdaq due to non-compliance with the $1.00 minimum bid price rule and the $2.5 million stockholders’ equity requirement. The suspension is expected to take effect at the open of business on February 10, 2026, unless a Nasdaq Listing and Hearing Review Council stay is granted. BioAtla has requested an immediate call for review and plans to appeal the delisting determination, but these actions do not automatically halt the suspension. If delisted from Nasdaq, the company expects its shares to trade on the OTCIQ market under the symbol BCAB, which it warns could materially hurt trading price and volume. The company also notes that $1.25 million of prepaid advance principal remains outstanding and that its $15.0 million standby equity purchase agreement cannot be used while Nasdaq trading is suspended.
BioAtla outlined a path to reduce its share count and address Nasdaq listing issues. The company used a single super-voting Series A Junior Preferred Share to help approve a reverse stock split proposal, then redeemed that share and filed a Certificate of Elimination to remove the series from its charter.
The board chose not to implement the approved reverse split while listed on Nasdaq and instead signed a Merger Agreement under which a wholly owned subsidiary will merge into BioAtla and every 50 common shares will convert into one share, subject to stockholder approval. BioAtla detailed ongoing challenges meeting Nasdaq bid price and equity/market value standards, warning that failure to regain compliance by early February 2026 could lead to suspension and delisting.
The company also highlighted an expected $5 million payment from Inversagen AI for 4.375% of units in a subsidiary SPV and the filing of a new Form S-3 shelf registration to replace an expiring universal shelf and register shares for existing financing agreements.
BioAtla, Inc. reported that its board authorized the issuance of one share of Series A Junior Preferred Stock, called a Super-Voting Share, to Chairman and CEO Jay M. Short, Ph.D., for $0.01. This unregistered sale relied on the Section 4(a)(2) exemption for a private transaction with an accredited investor.
The company filed a Certificate of Designation creating the Super-Voting Share. This share votes together with common stock solely on reverse stock split–related proposals and any adjournments or related matters. It carries votes equal to the number of common shares outstanding on the record date, but must vote “for” the proposal only if at least two-thirds of the voting power of common stock present favors it, and “against” otherwise. The Super-Voting Share has no dividend rights, a $0.01 liquidation preference, can be redeemed by the board for $0.01, is generally non-transferable, and receives no merger consideration.
The filing explains that at a prior special meeting, stockholders approved a stock issuance proposal and an adjournment proposal, but the reverse stock split proposal (at a 1-for-5 to 1-for-20 range) did not receive the required two-thirds vote, so the meeting was adjourned. The special meeting will reconvene on January 26, 2026 with a new record date of January 12, 2026, and the Super-Voting Share is designed to help secure approval of the reverse stock split if the two-thirds support threshold among common shares present is reached.
BioAtla, Inc. entered into two financing arrangements that together provide access to up to $22.5 million in capital. The company agreed to a $7.5 million Pre-Paid Advance with Yorkville and Anson funds, for which it will receive approximately $7.13 million in gross proceeds as the advance is purchased at 95% of face value. The advance bears 4% annual interest, includes a 10% payment premium, matures 12 months after closing, and can be repaid in cash or through share issuances priced off the stock’s VWAP, subject to a floor price and Nasdaq rules.
Separately, BioAtla entered into a Standby Equity Purchase Agreement with Yorkville allowing it to sell up to $15.0 million of common stock over 36 months at 97% of the lowest VWAP over a three-day period for each draw. Yorkville received a $300,000 commitment fee paid in 243,428 shares at $1.2324 per share. Both arrangements are subject to a 4.99% ownership cap per investor and an overall 19.99% Nasdaq exchange cap on shares issuable unless stockholders approve issuances above that level.
BioAtla, Inc. (BCAB) furnished an 8-K announcing its Q3 2025 results and a clinical program update. The company reported that a press release covering the quarter ended September 30, 2025 has been provided as Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is being furnished, not filed, and will not be incorporated by reference into other filings. BioAtla’s common stock trades on The Nasdaq Capital Market under the symbol BCAB.
BioAtla, Inc. reports that a Nasdaq Hearings Panel has granted its request for continued listing, subject to specific conditions and deadlines. The company must apply to transfer its shares to The Nasdaq Capital Market by September 26, 2025, demonstrate compliance with Nasdaq’s minimum stockholders’ equity requirement by December 31, 2025, and meet the minimum bid price requirement by February 2, 2026. BioAtla submitted its application to transfer on September 18, 2025 and believes it can regain compliance with both requirements, though it cautions there is no assurance this will occur. The company also highlights risks including factors that raise substantial doubt about its ability to continue as a going concern and its need for additional funding to continue developing its CAB technology platform and product candidates.
BioAtla, Inc. (Nasdaq: BCAB) filed a Form 8-K covering two routine corporate matters: approval of its 2025 Corporate Bonus Plan and the final results of its 2025 Annual Meeting of Stockholders.
2025 Corporate Bonus Plan (Item 5.02): On 17 June 2025 the Board’s Compensation Committee adopted a cash-based incentive plan for the Chief Executive Officer, Chief Financial Officer and Chief Medical Officer. Payouts are driven by four weighted corporate performance goals—clinical development milestones (25%), financing objectives (50%), financial & people objectives (20%), and brand awareness (5%). A minimum threshold of 50 % aggregate achievement is required for any payout; actual bonuses may range from 50 % to 125 % of the executive’s target opportunity. Target bonuses are set as a percentage of base salary: 60 % for CEO Jay Short and 40 % for both CFO Richard Waldron and CMO Eric Sievers.
Annual Meeting results (Item 5.07): Held virtually on 18 June 2025, the meeting reached a quorum with 30,358,471 shares (≈52 % of shares outstanding) represented. Shareholders re-elected three Class II directors for three-year terms, with Lawrence Steinman, M.D. receiving the highest support (11.6 million votes for). Ernst & Young LLP was ratified as independent auditor for FY 2025 (30.2 million votes for; 99.5 % support). A non-binding “say-on-pay” resolution passed with 8.96 million votes in favor versus 4.49 million against.
No other material transactions, earnings data, or strategic changes were disclosed in this filing.